Fig. 1

TGFβ inhibitors selectively regulate SMAD2/3 phosphorylation in human primary MPCs. (A) Primary MPCs were treated with ALK5 inhibitors SB431542 or Galunisertib/LY2157299 [0.3 µM, 1 µM, and 3 µM]. SB431542 and Galunisertib/LY2157299 treatments were performed simultaneously with the TGFβ [10 ng/mL] treatment for 30 min. (B) Primary MPCs were treated with SMAD3 inhibitors Halofuginone [3 nM, 10 nM, and 30 nM] or SIS3 [5 µM, 10 µM, and 20 µM]. Halofuginone treatment was performed for 24 h before TGFβ [10 ng/mL] treatment for 30 min and SIS3 treatment was performed for 24 h before TGFβ [10 ng/mL] treatment for 15 min. GAPDH was used as the loading control. DMSO treatment was used as vehicle control. Molecular weight is shown in Kilodaltons (kDa). TGFB = TGFβ, SB = SB431542, LY = Galunisertib/LY2157299, Halo = Halofuginone.